Dalmau Llorca, Maria RosaAguilar Martín, CarinaCarrasco Querol, NoèliaHernández Rojas, ZojainaForcadell Drago, EmmaRodríguez Cumplido, DoloresPepió i Vilaubí, Josep M.Castro Blanco, ElisabetGonçalves, Alessandra QueirogaFernández Sáez, José2021-03-262021-03-262021-02-24https://hdl.handle.net/2445/175799Background: Oral anticoagulants (OAs) are the treatment to prevent stroke in atrial fibrillation (AF). Anticoagulant treatment choice in non-valvular atrial fibrillation (NVAF) must be individualized, taking current guidelines into account. Adequacy of anticoagulant therapy under the current criteria for NVAF in real-world primary care is presented. Methods: Cross-sectional study, with real-world data from patients treated in primary care (PC). Data were obtained from the System for the Improvement of Research in Primary Care (SIDIAP) database, covering 60,978 NVAF-anticoagulated patients from 287 PC centers in 2018. Results: In total, 41,430 (68%) were treated with vitamin K antagonists (VKAs) and 19,548 (32%) NVAF with direct-acting oral anticoagulants (DOACs). Inadequate prescription was estimated to be 36.0% and 67.6%, respectively. Most DOAC inadequacy (77.3%) was due to it being prescribed as a first-line anticoagulant when there was no history of thromboembolic events or intracranial hemorrhage (ICH). A total of 22.1% had missing estimated glomerular filtration rate (eGFR) values. Common causes of inadequate VKA prescription were poor control of time in therapeutic range (TTR) (98.8%) and ICH (2.2%). Conclusions: Poor adequacy to current criteria was observed, being inadequacy higher in DOACs than in VKAs. TTR and GFR should be routinely calculated in electronic health records (EHR) to facilitate decision-making and patient safety.16 p.application/pdfengcc by (c) Dalmau Llorca et al., 2021http://creativecommons.org/licenses/by/3.0/es/Fibril·lació auricularAnticoagulants (Medicina)Atrial fibrillationAnticoagulants (Medicine)info:eu-repo/semantics/article2021-03-25info:eu-repo/semantics/openAccess33668315